Mobidiag has received CE-IVD marking for its Novodiag® Stool Parasites qPCR and microarray platform. The system detects nucleic acid markers corresponding to helminths, protozoans, and microsporidia, with a >95% coverage of all intestinal parasites.  

Microscopic morphological analysis has been the gold standard in this area but a lack of expertise has seen a rise in parasitic intestinal disease in developed countries and remains one of the main causes of infections and death in developing countries.

Intestinal parasitic infections can cause serious illness in immunocompromised persons and can also fight for nutrients and cause malnourishment to people in poor areas. With an expected rise in temperatures on the horizon, ecological models show a third of parasites to become extinct. Although this might seem a benefit, experts say that this could open up new ecosystems for more harmful opportunistic parasites.

This syndromic test is designed to run on-demand using the automated Novodiag® system and can detect the presence of nucleic acid markers corresponding to the identification of the most common protozoan, helminths, and microsporidia from stool samples. The test provides complete results in 90 minutes with less than five minutes of hands-on time by an operator.

The Novodiag® Stool Parasites test come equipped with a ready to use test cartridge containing everything necessary to perform the assay and is easily disposable. 

Established in 2000, Mobidiag has served the European clinical diagnostics market with its multiplex Prove-it™ product family since 2008. In 2013, Mobidiag (Finland) merged with a diagnostic platform developer Genewave (France) and a stool-based clinical assay development company Amplidiag (Finland).